"Klinikverbund Kempten-Oberallgäu gGmbH"
Welcome,         Profile    Billing    Logout  
 3 Trials 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Felberbaum, Ricardo
NCT03353831 / 2017-000202-37: Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Checkmark Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Checkmark AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).
Recruiting
3
664
Europe
Bevacizumab, Atezolizumab, Chemotherapy, Placebos
AGO Research GmbH, Hoffmann-La Roche
Recurrent Ovarian Carcinoma
12/23
12/24

Download Options